drugset / Trial / NCT04348513
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
Phase 2
Terminated
5 enrolled
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Attikon Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is a phase II, parallel, prospective, randomized, double-blind, placebo controlled trial. The present study will aim to address the efficacy and safety of acute administration of triiodothyronine on ICU patients diagnosed with pulmonary infection due to COVID-19 and require mechanical respiratory support or ECMO.
Timeline
- Start
- 2020-05-29
- Primary completion
- 2021-04-19
- Completion
- 2021-04-19
Publications
- Pantos C, Apostolaki V, Kokkinos L, Trikas A, Mourouzis I. Acute triiodothyronine treatment and red blood cell sedimentation rate (ESR) in critically ill COVID-19 patients: A novel association? Clin Hemorheol Microcirc. 2021;79(3):485-488. doi: 10.3233/CH-211215.
- Pantos C, Kostopanagiotou G, Armaganidis A, Trikas A, Tseti I, Mourouzis I. Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 26;21(1):573. doi: 10.1186/s13063-020-04474-0.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liothyronine | Small molecule | 0.057 g/kg | Intravenous |